Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation

Cancer Letters

Volumn 298, Issue 1, 2010, Pages 88-98

  Park, In Ja ^a   Kim, Min Jung ^a   Park, Ock Jin ^b   Park, Myoung Gyu ^c   Choe, Wonchae ^a   Kang, Insug ^a   Kim, Sung Soo ^a   Ha, Joohun ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Hannam University Daedeok Valley Campus ^*  (South Korea)

^c Mazence Co Ltd   (South Korea)

Author keywords

Apoptosis; Bcl 2; Cryptotanshinone; DU145 prostate cancer cells; Fas mediated apoptosis; MAPK

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CRYPTOTANSHINONE; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; FAS LIGAND; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PHENANTHRENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ISOLATION; DRUG SENSITIZATION; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SALVIA MILTIORRHIZA; STRUCTURE ANALYSIS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; HELA CELL LINE; IMMUNOLOGY; JURKAT CELL LINE; MALE; METABOLISM; MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FAS LIGAND PROTEIN; HELA CELLS; HUMANS; JURKAT CELLS; MALE; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENANTHRENES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

SALVIA MILTIORRHIZA;

EID: 77956945287     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.06.006     Document Type: Article

References (40)

1. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
2. Makin G., Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol. 2001, 11:S22-S26.
3. Guchelaar H.J., Vermes A., Vermes I., Haanen C. Apoptosis: molecular mechanisms and implications for cancer chemotherapy. Pharm. World Sci. 1997, 19:119-125.
4. Yamada T., Ohyama H. Radiation and apoptosis. Gan To Kagaku Ryoho 1994, 21:602-607.
5. Green D.R., Ferguson T.A. The role of Fas ligand in immune privilege. Nat. Rev. Mol. Cell Biol. 2001, 2:917-924.
6. Wajant H. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat. Res. 2006, 130:141-165.
7. Mizuno T., Zhong X., Rothstein T.L. Fas-induced apoptosis in B cells. Apoptosis 2003, 8:451-460.
8. Konopleva M., Zhao S., Xie Z., Segall H., Younes A., Claxton D.F., Estrov Z., Kornblau S.M., Andreeff M. Apoptosis. Molecules and mechanisms. Adv. Exp. Med. Biol. 1999, 457:217-236.
9. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002, 296:1635-1636.
10. Srivastava R.K., Sasaki C.Y., Hardwick J.M., Longo D.L. Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J. Exp. Med. 1999, 190:253-265.
11. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2:277-288.
12. Kawahara A., Kobayashi T., Nagata S. Inhibition of Fas-induced apoptosis by Bcl-2. Oncogene 1998, 17:2549-2554.
13. Straszewski-Chavez S.L., Abrahams V.M., Funai E.F., Mor G. X-linked inhibitor of apoptosis (XIAP) confers human trophoblast cell resistance to Fas-mediated apoptosis. Mol. Hum. Reprod. 2004, 10:33-41.
14. Pullar J.M., Thomson S.J., King M.J., Turnbull C.I., Midwinter R.G., Hampton M.B. The chemopreventive agent phenethyl isothiocyanate sensitizes cells to Fas-mediated apoptosis. Carcinogenesis 2004, 25:765-772.
15. Kaufmann S.H., Earnshaw W.C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 2000, 256:42-49.
16. Shyur L.F., Chen C.H., Lo C.P., Wang S.Y., Kang P.L., Sun S.J., Chang C.A., Tzeng C.M., Yang N.S. Induction of apoptosis in MCF-7 human breast cancer cells by phytochemicals from Anoectochilus formosanus. J. Biomed. Sci. 2004, 11:928-939.
17. Suh S.J., Jin U.H., Choi H.J., Chang H.W., Son J.K., Lee S.H., Jeon S.J., Son K.H., Chang Y.C., Lee Y.C., Kim C.H. Cryptotanshinone from Salvia miltiorrhiza Bunge has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-kappaB and AP-1. Biochem. Pharmacol. 2006, 72:1680-1689.
18. Shi Z., He J., Yao T., Chang W., Zhao M. Simultaneous determination of cryptotanshinone, tanshinone I and tanshinone IIA in traditional Chinese medicinal preparations containing Radix Salvia miltiorrhiza by HPLC. J. Pharm. Biomed. Anal. 2005, 37:481-486.
19. Hur J.M., Shim J.S., Jung H.J., Kwon H.J. Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. Exp. Mol. Med. 2005, 37:133-137.
20. Jin D.Z., Yin L.L., Ji X.Q., Zhu X.Z. Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression. Eur. J. Pharmacol. 2006, 549:166-172.
21. Akar U., Chaves-Reyez A., Barria M., Tari A., Sanguino A., Kondo Y., Kondo S., Arun B., Lopez-Berestein G., Ozpolat B. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy 2008, 4:669-679.
22. Broker L.E., Kruyt F.A., Giaccone G. Cell death independent of caspases: a review. Clin. Cancer Res. 2005, 11:3155-3162.
23. Wada T., Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23:2838-2849.
24. Seger R., Krebs E.G. The MAPK signaling cascade. Faseb J. 1995, 9:726-735.
25. Tanaka T., Yoshimi M., Maeyama T., Hagimoto N., Kuwano K., Hara N. Resistance to Fas-mediated apoptosis in human lung fibroblast. Eur. Respir. J. 2002, 20:359-368.
26. Krab L.C., Goorden S.M., Elgersma Y. Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases. Trends Genet. 2008, 24:498-510.
27. Ding X.Z., Tong W.G., Adrian T.E. 12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation. Int. J. Cancer 2001, 94:630-636.
28. Ichijo H., Nishida E., Irie K., ten Dijke P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K., Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275:90-94.
29. Mansouri A., Ridgway L.D., Korapati A.L., Zhang Q., Tian L., Wang Y., Siddik Z.H., Mills G.B., Claret F.X. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J. Biol. Chem. 2003, 278:19245-19256.
30. Kim H.S., Hwang J.T., Yun H., Chi S.G., Lee S.J., Kang I., Yoon K.S., Choe W.J., Kim S.S., Ha J. Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. J. Biol. Chem. 2008, 283:3731-3742.
31. Han J.Y., Fan J.Y., Horie Y., Miura S., Cui D.H., Ishii H., Hibi T., Tsuneki H., Kimura I. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol. Ther. 2008, 117:280-295.
32. Pan Y., Bi H.C., Zhong G.P., Chen X., Zuo Z., Zhao L.Z., Gu L.Q., Liu P.Q., Huang Z.Y., Zhou S.F., Huang M. Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza). Xenobiotica 2008, 38:382-398.
33. Zhou L., Zuo Z., Chow M.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 2005, 45:1345-1359.
34. Kim E.J., Jung S.N., Son K.H., Kim S.R., Ha T.Y., Park M.G., Jo I.G., Park J.G., Choe W., Kim S.S., Ha J. Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Mol. Pharmacol. 2007, 72:62-72.
35. Palakurthi S.S., Aktas H., Grubissich L.M., Mortensen R.M., Halperin J.A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res. 2001, 61:6213-6218.
36. Govindarajan R., Ratnasinghe L., Simmons D.L., Siegel E.R., Midathada M.V., Kim L., Kim P.J., Owens R.J., Lang N.P. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J. Clin. Oncol. 2007, 25:1476-1481.
37. Galli A., Ceni E., Crabb D.W., Mello T., Salzano R., Grappone C., Milani S., Surrenti E., Surrenti C., Casini A. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut 2004, 53:1688-1697.
38. Meisterfeld R., Ehehalt F., Saeger H.D., Solimena M. Pancreatic disorders and diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 2008, 116(Suppl. 1):S7-S12.
39. La Vecchia C., Negri E., Franceschi S., D'Avanzo B., Boyle P. A case-control study of diabetes mellitus and cancer risk. Brit. J. Cancer 1994, 70:950-953.
40. Gullo L., Pezzilli R., Morselli-Labate A.M. Diabetes and the risk of pancreatic cancer. New Engl. J. Med. 1994, 331:81-84.